Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects

Pfizer said it still plans to release phase two trial data on a once-a-day version of its weight loss drug, known as danuglipron, in mid-2024.

...

'You barely knew what we were actually selling': Gap CEO Richard Dickson on the brand's heavy discount strategy

2 weeks ago

Exxon Mobil CEO urges COP28 to focus on reducing emissions — not phasing out fossil fuels

1 week ago

Fed Chair Powell calls talk of cutting rates 'premature' and says more hikes could happen

2 weeks ago

How $100 billion mining giant Rio Tinto is poised to benefit from the EV boom

1 week ago

Pfizer's twice-daily weight loss pill joins a long list of obesity drug flops

1 week ago